Ownership and insider activity for Ernexa Therapeutics Inc. (ERNA): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases. Its flagship candidate, ERNA-101, is an allogeneic iMSC designed to release pro-inflammatory cytokines, namely IL-7 and IL-15, intended for the treatment of ovarian cancer.
Price
| Price | $3.91 |
| Market Cap | $1M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-31 | Bristol James Arthur | A-Award | 8,320 | $38K |
| 2026-08-31 | Bristol James Arthur | A-Award | 5,083 | $23K |
| 2026-08-31 | Cicala Peter | A-Award | 5,943 | $27K |
| 2026-08-31 | Cicala Peter | A-Award | 5,083 | $23K |
| 2026-08-31 | Polinsky David | A-Award | 5,083 | $23K |
| 2026-08-31 | Wexler William A. | A-Award | 5,943 | $27K |
| 2026-08-31 | Ratner Elena | A-Award | 5,944 | $27K |
| 2026-08-31 | Luther Sanjeev | A-Award | 118,848 | $543K |
| 2026-08-04 | Polinsky David | |||
| 2026-02-10 | Polinsky David | 8,000 | $136K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.7M | $3.4M | $2.6M | $3.3M | $1.6M | $17.0M | $11.4M | $7.6M | $1.7M | $1.9M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $928000 | $714000 | $1.1M | $1.2M | 0 | $684000 | $951000 | $425000 | $437000 | $95000 |
| Inventory | $3.0M | $4.9M | $2.5M | $1.1M | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $10.7M | $9.6M | $6.8M | $6.1M | $1.7M | $18.8M | $13.7M | $9.6M | $2.4M | $3.1M |
| Property, Plant & Equipment | $3.1M | $3.7M | $4.7M | $4.9M | $2.7M | $3.2M | $1.3M | $33.3M | $755000 | $547000 |
| Goodwill | $937000 | $1.0M | $667000 | $696000 | $2.0M | $2.0M | $2.0M | $2.0M | $2.0M | $2.0M |
| Intangible Assets | 0 | 0 | 0 | $1.9M | $6.0M | $6.0M | 0 | 0 | 0 | 0 |
| Total Assets | $17.1M | $16.6M | $14.9M | $15.3M | $12.9M | $31.5M | $22.3M | $49.1M | $5.3M | $5.8M |
| Accounts Payable | $247000 | $390000 | $271000 | $835000 | $1.3M | $1.8M | $1.6M | $1.1M | $1.7M | $1.1M |
| Short-term Debt | $3.1M | $5.2M | $1.0M | $3.2M | $526000 | 0 | $1.8M | 0 | $207000 | $213000 |
| Total Current Liabilities | $6.6M | $10.7M | $4.0M | $6.1M | $3.1M | $3.7M | $7.7M | $6.6M | $2.9M | $3.1M |
| Long-term Debt | $5.1M | $8000 | $2.7M | 0 | $194000 | 0 | $1.2M | $6.8M | 0 | 0 |
| Total Liabilities | $13.1M | $11.0M | $7.9M | $10.2M | $5.2M | $6.0M | $10.2M | $46.9M | $3.6M | $3.4M |
| Retained Earnings | -$128.0M | -$129.1M | -$129.4M | -$131.5M | -$18.1M | -$140.7M | -$165.3M | -$187.0M | -$231.5M | -$245.6M |
| Total Equity | $4.1M | $5.5M | $6.9M | $5.1M | $7.7M | $25.5M | $12.1M | $2.2M | $1.7M | $2.4M |
| Total Debt | $8.5M | $5.4M | $3.8M | $6.1M | $2.9M | $2.7M | $4.1M | $41.8M | $684000 | $490000 |
| Net Debt | $2.8M | $2.0M | $1.2M | $2.8M | $1.3M | -$14.3M | -$7.3M | $34.3M | -$1.0M | -$1.4M |
| Working Capital | $4.0M | -$1.1M | $2.8M | -$25000 | -$1.4M | $15.1M | $6.0M | $3.0M | -$586000 | $20000 |
Financial Health
| Debt / Equity | 0.11 |
| Current Ratio | 2.01 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -62.89 |
Profitability
| Return on Equity | -305.85% |
| Return on Invested Capital | -328.05% |
| Return on Assets | -194.09% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ADAP · AEMD · AEON · DWTX · LNAI · MBRX · MPLT
Explore sector: Healthcare · Biotechnology
More sections of ERNA: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks